The flu shot lowers your chances of getting the flu, but it does not eliminate them. In recent seasons, vaccination has reduced the risk of needing a doctor visit for flu by roughly a quarter to two-fifths, depending on the year and the person’s age. The gap between “reduces risk” and “prevents entirely” surprises many people, and the reasons behind it reveal a lot about how flu vaccines work, why they sometimes disappoint, and why getting one still makes medical sense even when effectiveness numbers look modest.
How Effective Is the Flu Shot in a Typical Year?
The CDC tracks flu vaccine effectiveness (VE) every season using a network of outpatient clinics and hospitals. These numbers describe how much the vaccine lowers your odds of getting sick enough to visit a doctor or end up in the hospital compared to someone who wasn’t vaccinated. In the 2025–2026 season, for example, the vaccine reduced flu-related outpatient visits by about 24–36% across all ages and cut hospitalizations by around 31%.1National Institutes of Health. Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026 Children and adolescents fared better, with protection against hospitalization reaching about 41%, while adults over 65 saw around 31% protection against being hospitalized.1National Institutes of Health. Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026
Those numbers bounce around quite a bit from year to year. Looking back over two decades of CDC monitoring, some seasons have seen effectiveness above 50%, while others dipped below 20%.2Centers for Disease Control and Prevention. CDC Seasonal Flu Vaccine Effectiveness Studies The pattern is consistent in one respect: VE tends to be higher against the H1N1 strain and influenza B than against H3N2.3Europe PMC. Influenza Vaccine Effectiveness: New Insights and Challenges H3N2 is the troublemaker of the flu world, mutating faster and dodging vaccine-generated immunity more easily than its relatives.
Why the Vaccine Works Better Some Years Than Others
Flu viruses are moving targets. Their surface proteins, especially hemagglutinin (the “H” in names like H3N2), change constantly through small mutations. This process, called antigenic drift, means the virus circulating in December may not look exactly like the virus researchers selected for the vaccine the previous February. Vaccine composition is reviewed before every flu season specifically because of this ongoing evolution, and a mismatch between vaccine strains and the strains that actually show up can substantially reduce protection.4Europe PMC. Models for predicting the evolution of influenza to inform vaccine strain selection
Surveillance work illustrates how this plays out in real time. In the 2024–2025 winter season in Saudi Arabia, circulating H3N2 strains belonged to the same broad genetic group as the vaccine strain, yet researchers identified four amino acid differences in the hemagglutinin protein that distinguished them from the vaccine virus.5PubMed Central. Genetic characterization of influenza A (A/H3N2) viruses reveals antigenic drift in receptor binding domain and possible vaccine mismatch in strains circulating in Riyadh, Saudi Arabia, 2024-2025 A similar story unfolded in Romania across three consecutive seasons, where highly diverse H3N2 strains with significant mutations compared to the vaccine strain likely contributed to lower vaccine performance in 2021–2022.6PubMed Central. Antigenic Divergence from the Seasonal Vaccine of the Influenza Virus Strains Circulating in Romania During Three Successive Seasons (2021-2024)
Predicting which strains will dominate months in advance is genuinely hard. Researchers use computational models and global surveillance networks to make their best guess, but the virus does not always cooperate. When the match is close, the vaccine performs well. When the virus zigs after the vaccine was designed for a zag, effectiveness drops.
The Egg Problem
Strain mismatch isn’t the only issue. Most flu vaccines are still manufactured by growing the virus in fertilized chicken eggs, a method that dates back decades. When human flu viruses replicate in avian cells, they sometimes pick up mutations in the hemagglutinin protein that help them grow better in eggs but change the way the protein looks to the human immune system. The result: the vaccine virus no longer perfectly matches the virus it was supposed to train your immune system to recognize.7Elsevier. The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness
Expert estimates suggest that egg-adaptation changes reduce vaccine effectiveness by roughly 4–16%, with the biggest hit coming against H3N2 viruses.8MDPI. Estimation of Reduction in Influenza Vaccine Effectiveness Due to Egg-Adaptation Changes—Systematic Literature Review and Expert Consensus This was dramatically illustrated during the 2012–2013 season, when low vaccine effectiveness turned out to be driven not by drift in circulating viruses but by mutations the vaccine strain picked up during egg production. The circulating H3N2 viruses actually matched the recommended prototype well; it was the egg-adapted version used in the actual vaccine that had drifted away.9PubMed Central. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses
Cell-based and recombinant vaccines that skip eggs altogether avoid this problem, and they are increasingly available. If you have ever wondered why your pharmacist offers you a choice of vaccine types, this is one of the reasons.
The Vaccine Is Better at Keeping You Out of the Hospital Than Out of Bed
One point that often gets lost in conversations about flu shot effectiveness is that the vaccine does more than just try to prevent infection. Even when it fails to stop you from catching the flu, it tends to make the illness less severe. Data from the 2023–2024 season showed the vaccine was about 58% effective at preventing hospitalization and emergency visits in children and adolescents, and about 39% effective against hospitalization in adults.10Oxford Academic. Influenza Vaccine Effectiveness Against Hospitalizations and Emergency Department or Urgent Care Encounters for Children, Adolescents, and Adults During the 2023–2024 Season, United States
The distinction matters because flu is not just an inconvenience. In bad seasons, it kills tens of thousands of people in the United States alone, and hundreds of thousands are hospitalized. A vaccine that cuts hospitalizations by a third to a half is doing serious work, even if it doesn’t stop every sore throat and fever. The people who say “I got the flu shot and still got sick” may be right, but they may also have avoided a much worse version of that illness.
Why Protection Fades as the Season Goes On
Antibody levels from flu vaccination peak about a month after the shot and then steadily decline. Research tracking antibody levels after the 2018 seasonal vaccine found they had dropped by three months post-vaccination, though they remained above pre-vaccination levels at six months across all age groups.11Wiley Online Library. Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months That’s a meaningful window, but flu season can stretch from October through May, which means someone vaccinated in September may have substantially lower antibody levels by the time a late-season wave arrives.
Modeling work suggests that genuine waning of immune protection accounts for a significant portion of the decline in measured vaccine effectiveness observed over the course of a flu season, though it isn’t the whole story. Depending on the strain, waning explained anywhere from about 16% to 53% of the observed drop in effectiveness.12PubMed Central. Waning of Measured Influenza Vaccine Effectiveness Over Time: The Potential Contribution of Leaky Vaccine Effect This is part of why public health authorities try to time vaccination campaigns for early fall, balancing the need for protection to last through the peak season against the reality that antibodies start declining within weeks.
Does Getting the Shot Every Year Weaken It Over Time?
This is one of the more counterintuitive questions in flu vaccine science, and the answer is complicated. A large systematic review found that getting vaccinated the previous year does somewhat reduce the effectiveness of this year’s shot. But the same analysis found that people vaccinated in two consecutive years were still better protected than people who skipped vaccination entirely.13The Lancet. Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis In other words, the best move is still to get vaccinated annually, even if there is a modest cost to doing so repeatedly.
A study of healthcare workers added some nuance: repeated annual vaccination increased how long antibodies persisted, which is a good thing. But getting the same vaccine virus more than three times in a row seemed to blunt the antibody response to subsequent shots. When the vaccine virus was updated to a new strain, antibody responses improved again.14Nature. Effects of repeated influenza vaccination and infection on durable seroprotection in healthcare workers The takeaway is that the immune system responds best to novelty. When the vaccine changes to track a new circulating strain, your immune system pays attention. When it sees the same thing again, it’s less enthusiastic.
Your First Flu Shapes a Lifetime of Responses
The flu strain you were exposed to first as a child leaves a lasting stamp on your immune system. Researchers call this immune imprinting. Your immune system builds its strongest, most durable memory against the first flu virus it encounters, and that memory influences how it responds to every flu strain you meet afterward, whether through infection or vaccination.15Europe PMC. Influenza Vaccines Delivered in Early Childhood Could Turn Antigenic Sin into Antigenic Blessings
Analysis of 54 years of U.S. influenza mortality data found strong evidence that your birth cohort, and by extension the flu strain dominant during your childhood, shapes your mortality risk from flu throughout your life. People whose first flu exposure was to a strain more similar to the one circulating later had greater protection during H1N1-dominated seasons after the 2009 pandemic.16PubMed Central. Childhood immune imprinting shapes cohort and period influenza mortality This means two people sitting next to each other in a doctor’s waiting room, both vaccinated, could respond to the same flu season very differently based on something that happened when they were toddlers.
Some researchers see this as an opportunity rather than a limitation. If the immune system’s first impression is so powerful, then vaccinating infants before their first natural flu infection could potentially shape their immune responses in a beneficial direction for life.15Europe PMC. Influenza Vaccines Delivered in Early Childhood Could Turn Antigenic Sin into Antigenic Blessings
What the Vaccine Does Beyond Antibodies
Most discussions of flu vaccine effectiveness focus on antibodies, the proteins that latch onto the virus and neutralize it. But your immune system has another major arm: T cells. These cells don’t prevent infection the way antibodies do, but they recognize and kill infected cells, limiting how far the virus spreads inside your body. T cell responses tend to be more cross-reactive than antibody responses, meaning they can recognize flu strains that look quite different from the one the vaccine was designed for.17Europe PMC. T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine
Work on live attenuated influenza vaccine (the nasal spray version) in children showed that it boosted T cells that responded not just to the vaccine strains but also to drifted strains that circulated the following year. These cross-reactive T cells persisted for at least six months after vaccination.18Oxford University Press. Boosting of Cross-Reactive and Protection-Associated T Cells in Children After Live Attenuated Influenza Vaccination Standard effectiveness measurements, which are based on whether someone tests positive for flu after visiting a clinic, mostly capture the antibody side of the equation. The T cell contribution to reducing severity and shortening illness is harder to measure in population-level studies, but it likely explains some of the gap between “didn’t prevent infection” and “kept the person out of the hospital.”
There is also intriguing evidence that the flu vaccine triggers broader, nonspecific changes in the innate immune system. A small proof-of-principle study found that a standard inactivated flu vaccine reprogrammed innate immune cells in ways that boosted their response to unrelated viral threats, including SARS-CoV-2.19PubMed Central. Induction of trained immunity by influenza vaccination – impact on COVID-19 This “trained immunity” effect is still being explored, and it is far from settled science, but it suggests the flu shot’s benefits extend beyond the specific strains printed on the label.
Protecting People Around You
Even if the vaccine doesn’t perfectly protect the person who receives it, widespread vaccination in a community reduces how much the virus circulates. This indirect protection matters most for people who can’t be vaccinated or who respond poorly to the vaccine. A school-based vaccination study found that unvaccinated children were significantly less likely to get the flu in schools where about half the students had been vaccinated, compared with schools where few students were vaccinated.20Oxford Academic. School-Located Influenza Vaccination Decreases Laboratory-Confirmed Influenza and Improves School Attendance The infection rate in the vaccinated school was less than half that in the control schools. Your flu shot is not just about you; it’s a form of protection for the people in your orbit who are most vulnerable.
Why Older Adults Often Get Less Protection
Immune function declines with age. The thymus, which produces T cells, gradually shrinks. Antibody responses become slower and weaker. Chronic low-grade inflammation increases. All of this means the standard flu shot tends to produce a weaker immune response in older adults, which is reflected in the consistently lower VE numbers seen in people over 65.1National Institutes of Health. Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026
Enhanced vaccine formulations have been developed specifically to address this gap. High-dose vaccines contain four times the antigen of standard shots. Adjuvanted vaccines include immune-stimulating compounds that amplify the body’s response. Research suggests these enhanced approaches help overcome the age-related decline in immune function.21Elsevier. Seasonal influenza vaccination: Overcoming immunosenescence with enhanced vaccines If you are over 65 or caring for someone who is, it is worth asking specifically about high-dose or adjuvanted options.
The Nasal Spray vs. the Shot
For children, two main delivery options exist: the traditional injection (inactivated vaccine) and the nasal spray (live attenuated vaccine). A systematic review comparing these head-to-head in children found no clear overall difference in efficacy between the quadrivalent nasal spray and the inactivated injection. However, when the analysis was narrowed to large multi-center trials, the trivalent nasal spray came out ahead of the trivalent injection.22PubMed Central. Head-to-head comparison of influenza vaccines in children: a systematic review and meta-analysis The nasal spray also appears to be better at generating those cross-reactive T cell responses mentioned earlier, which could provide broader protection against drifted strains. For needle-averse kids, the nasal spray is a reasonable choice that may carry some immunological advantages.
How Effectiveness Is Actually Measured
The way flu vaccine effectiveness is measured matters for how you interpret the numbers. Most modern VE studies use what’s called a test-negative design: patients showing up with flu-like symptoms get tested, and researchers compare how many of the flu-positive patients were vaccinated versus how many of the flu-negative patients were vaccinated. The difference tells you how much the vaccine reduced the odds of having confirmed flu. The accuracy of the test itself matters. Simulation studies have shown that when rapid tests (which are less accurate than laboratory-grade PCR testing) are used as the outcome measure, true vaccine effectiveness of 50% gets underestimated at around 41%, and a true 70% looks like about 57%.23Elsevier. Basic principles of test-negative design in evaluating influenza vaccine effectiveness The VE numbers reported by the CDC are based on PCR-confirmed cases, so they’re more reliable, but it’s worth knowing that effectiveness in real life could be slightly different from what any single study captures.
What Your Gut Might Have to Do With It
An emerging line of research links the composition of your gut bacteria to how well you respond to vaccines, including the flu shot. The gut microbiome influences T cell development, antibody production, and the signaling molecules that coordinate immune responses. Certain bacterial species, including members of the Bifidobacterium group, have been associated with stronger immune responses to vaccination.24Taylor & Francis Online (Gut Microbes). The emerging role of the gut microbiota in vaccination responses This research is still in its early stages, and nobody is prescribing specific probiotics to boost your flu shot response yet. But it helps explain why two people can get the same vaccine and have very different outcomes: the state of your immune system at the time of vaccination, shaped by factors as varied as your diet, your antibiotic history, and your microbial community, affects how well the shot works for you personally.
The Quest for a Universal Flu Vaccine
All of the limitations described above stem from a core problem: current flu vaccines target the parts of the virus that change the fastest. The head of the hemagglutinin protein is the main target, and it’s the part that mutates most readily. A universal flu vaccine would instead target conserved regions of the virus, the parts that stay relatively stable across strains and even across subtypes. One approach focuses on the stem of the hemagglutinin protein rather than the head. A phase 1/2a trial of a stem-based vaccine showed it could generate broad antibody responses against multiple influenza strains, suggesting this approach may eventually reduce the need for annual reformulation.25Nature Communications. A group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1/2a study
A universal vaccine is still years from clinical use, but the field has made more progress in the last decade than in the previous several. Several candidates are in various stages of clinical trials, and the experience gained from mRNA vaccine development during the COVID-19 pandemic has accelerated the timeline. If one of these candidates works, the annual guessing game of strain selection could become a thing of the past, and flu vaccine effectiveness could become far more consistent from year to year.